Jason Haas - 29 Jun 2022 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role
Director
Signature
By: Charles S. Berkman For: Jason Haas
Issuer symbol
LGND
Transactions as of
29 Jun 2022
Net transactions value
$0
Form type
4
Filing time
30 Jun 2022, 18:32:37 UTC
Previous filing
17 Feb 2022
Next filing
11 Oct 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LGND Common Stock Award $0 +1,750 $0.000000 1,750 29 Jun 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LGND Non-Qualified Stock Option (right to buy) Award $0 +5,907 $0.000000 5,907 29 Jun 2022 Common Stock 5,907 $88.48 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option becomes exercisable in 3 successive annual installments upon completion of each calendar year of service beginning on the grant date.